The objectives of the review were to evaluate the clinical effectiveness and cost-effectiveness of trastuzumab in the management of advanced breast cancer. Only randomised controlled trials of trastuzumab alone, or in combination with other agents, versus systemic therapy without trastuzumab, were initially considered in the assessment of clinical effectiveness. The assessment of cost effectiveness includes only full economic evaluations. -- abstract.
